Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PM 00104

Drug Profile

PM 00104

Alternative Names: PM 00104/50; PM 10450; PM00104; Zalypsis®

Latest Information Update: 22 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaMar
  • Class Alkaloids; Antineoplastics; Small molecules
  • Mechanism of Action Cell cycle protein inhibitors; DNA binding protein modulators; Transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cervical cancer; Endometrial cancer; Ewing's sarcoma; Haematological malignancies; Lymphoma; Multiple myeloma; Solid tumours; Urogenital cancer

Most Recent Events

  • 26 Feb 2015 Phase II development is still ongoing
  • 29 Nov 2012 PM 00104 is available for licensing as of 29 Nov 2012.
  • 30 Apr 2012 PharmaMar completes a phase II trial in Ewing's sarcoma in USA, France and Italy (NCT01222767)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top